(PharmaNewsWire.Com, September 01, 2017 ) Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)-Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 12 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Musculoskeletal Disorders which include indications Dyskinesia, Anxiety Disorders, Autism, Depression, Schizophrenia, Cognitive Impairment Associated With Schizophrenia (CIAS), Major Depressive Disorder, Alcohol Addiction, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Chronic Pain, Cognitive Disorders, Cognitive Impairment, DiGeorge Syndrome, Fragile X Syndrome, Generalized Anxiety Disorder (GAD), Mania, Neurology, Opium (Opioid) Addiction, Pain, Parkinson's Disease, Spasmodic Torticollis and Substance (Drug) Abuse.
The latest report Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)-Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects.
-The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) -The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities -The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects -The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type -The report summarizes all the dormant and discontinued pipeline projects -The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage -Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) -Identify the use of drugs for target identification and drug repurposing -Identify potential new clients or partners in the target demographic -Develop strategic initiatives by understanding the focus areas of leading companies -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics -Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Addex Therapeutics Ltd Aevi Genomic Medicine Inc Bristol-Myers Squibb Company Eisai Co Ltd Eli Lilly and Company Heptares Therapeutics Ltd Johnson & Johnson Merz Pharma GmbH & Co KgaA Novartis AG Richter Gedeon Nyrt Sumitomo Dainippon Pharma Co Ltd Toray Industries Inc
Number of Products under Development by Stage of Development, H2 2017 9 Number of Products under Development by Therapy Areas, H2 2017 10 Number of Products under Development by Indications, H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13 Number of Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 15 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16 Number of Products under Investigation by Universities/Institutes, H2 2017 17 Products under Investigation by Universities/Institutes, H2 2017 18 Number of Products by Stage and Mechanism of Actions, H2 2017 20 Number of Products by Stage and Route of Administration, H2 2017 21 Number of Products by Stage and Molecule Type, H2 2017 22 Pipeline by Addex Therapeutics Ltd, H2 2017 23 Pipeline by Aevi Genomic Medicine Inc, H2 2017 23 Pipeline by Bristol-Myers Squibb Company, H2 2017 24 Pipeline by Eisai Co Ltd, H2 2017 24 Pipeline by Eli Lilly and Company, H2 2017 25 Pipeline by Heptares Therapeutics Ltd, H2 2017 25 Pipeline by Johnson & Johnson, H2 2017 26 Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017 26 Pipeline by Novartis AG, H2 2017 27 Pipeline by Richter Gedeon Nyrt, H2 2017 27 Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 28
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
